Nod-like receptor protein 3 and nod-like receptor protein 1 inflammasome activation in the hippocampal region of postmortem methamphetamine chronic user

Mahmoudiasl GR, Abbaszadeh HA, Rezaei-Tavirani M, Abdollahifar MA, Khoramgah MS, Niknazar S, Darabi S, Roozbahany NA

Hearing Disorders Research Center, Loghman Hakim Hospital and Department of Biology and Anatomical Sciences, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Dr.abbaszadeh@sbmu.ac.ir

ABSTRACT
OBJECTIVE AND BACKGROUND: Methamphetamine (Meth) is one of the most important central nervous system (CNS) stimulant abuse drugs that cause long-term or permanent damage to different regions of the brain, particularly hippocampus, by neuronal apoptosis and inflammation. In this study, we evaluated Nod-like Receptor Protein 3 (NLRP3) and Nod-like Receptor Protein 1 (NLRP1) inflammasome Activation in the Hippocampal Region of postmortem Meth Chronic User.

METHODS: Molecular and histological analyses were conducted on the brain of 14 non-addicted and 11 Meth users separately. The expression level of NLRP1, NLRP3 was measured using western blotting and immunohistochemistry (IHC) techniques. Histopathological assessment was performed with stereological Cell Counting of hippocampal cells stained with hematoxylin and eosin (H&E). Moreover, Tunel staining was carried out in order to detect any kind of DNA damage.

RESULTS: Based on our findings using western blotting and immunohistochemistry assay, overexpression of NLRP1 and NLRP3 proteins in the hippocampal region of Meth addicts was observed. The stereological analysis in the hippocampus of the human brain revealed increased neurodegeneration. Furthermore, the increased rate of apoptosis and cell death were significant and confirmed by Tunel assay in the hippocampus of Meth groups.

CONCLUSION: Chronic Meth abuse could result in increases of NLRP1 and NLRP3 and induction of inflammation and apoptosis in the hippocampus in Meth groups (Tab. 1, Fig. 9, Ref. 40). Text in PDF www.elis.sk.

KEY WORDS: methamphetamine, CA1, NLRP1, NLRP3.

Introduction

The abuse of Methamphetamine (Meth) has becomes widespread. Actually and it is considered as a growing problem. Meth is an extremely very addictive stimulant of the central nervous system (CNS). Its abuse is associated with many adverse side effects from which particularly, the dopaminergic and serotonergic systems of the brain are more prominent could be disrupted (1). Meth is a new recreational drug that causes severe damage to different parts of the brain (2). Meth is also known as sympathomimetic drug that can cause several physical and psychological side effects such as uncontrollable repetitive movements, sweating, pupil dilation and also severe behavioral reactions (3). According to the US Food and Drug Administration, about 38 million people reported having an addiction to Meth and related derivatives (4). Meth is the most commonly abused substance after cannabis. Chronic Meth abuse leads to neurodegeneration of cortex, hippocampus and midbrain areas which are related by memory deficits (5). Severe symptoms of Meth abuse appear to be due to changes in the hippocampus (6). Not only Meth inhibits neurogenesis in the ventral spatial processing region, but it is also apparent that it could prevent cell death in the behavior-regulatory region of the hippocampus (7). Microglia are the primary CNS immune cells. They are derived from the myeloid lineage and they are involved in the pathogenesis of many neurological disorders and in neurologic pathologies as well (8). Meth use can abuse could result in neurotoxicity which leads to microglial activation. This can which could be either be neuroprotective or pro-neurotoxic in the brain. Based on imaging studies, microglial activation is seen in areas of dopaminergic and serotonergic innervation in the brain of patients in Meth users.
addicts (9). Activation of Nod-like Receptor Protein 3 (NLRP3) inflammasome can cause neuroinflammation mediated by microglia- and degeneration of dopaminergic neuron (10). Meth is known to reason microglial stimulation and activation of NLRP3 which is a cytosolic protein complex and secretion of interleukin-1β (IL-1β) in an NLRP3 inflammasome-dependent way can induce secretion of several proinflammatory cytokines that are mediators of CNS inflammation during chronic stress and they play a key role in the induction of inflammation and the immune response development (11). Not only microbial infection but also endogenous signals of danger can cause the production of the NLRP3 inflammasome consisting of cytosolic sensor NLRP3, bridge protein apoptosis-associated speck-like protein containing a CARD (ASC), and cysteine protease caspase-1 (12-15). Meth-induced NLRP3 inflammasome signaling pathway and its contribution to microglial activation is still unclear. This pathway is implicated in the neuroinflammatory process and in mediating neuroinflammation in the CNS based on recent studies. The NLRPs have many subfamilies and they are associated with the development of several neurodegenerative disorders such as multiple sclerosis (MS), Alzheimer’s disease (AD) and Parkinson’s disease (PD). Many studies have been conducted in order to explain the role of NLRs in their pathogenesis. NLRP3 is a primary mediator of Meth-induced inflammasome activation and in this review we mainly focus on its role in microglia (14). Strong evidence indicates that NLRP3 inflammasome participate actively in chronic sterile CNS inflammation and cause harmful effects (16). The critical character of NLRP3 in promoting neuronal injury was extra demonstrated in traumatic-induced injury (17). Damage-associated molecular patterns (DAMPs) may be released in neurodegenerative disorders and acute neuronal injury, and are able to act as endogenous danger signals and initiate a cas-

Tab. 1. shows the profile of the participants in the study. These individuals are divided into two groups.

| The ultimate cause of death                      | Healthy dental pattern | Suicide attempt history | Duration of the consumption of meth (years) | Smoking history (years) | BMI   | Age (years) | Sampling time after death (h) | Sample number |
|-------------------------------------------------|------------------------|-------------------------|-------------------------------------------|-------------------------|-------|-------------|--------------------------------|---------------|
| MI                                              | 29                     | –                       | –                                         | 3                       | 26.4  | 41          | 1                              | N1            |
| Accidental                                      | 30                     | –                       | –                                         | 2                       | 21.9  | 26          | 4                              | N2            |
| MI                                              | 27                     | –                       | 2                                         | 2                       | 26.3  | 31          | 2                              | N3            |
| MI                                              | 28                     | 1                       | 7                                         | 30.7                    | 35    | 1           | N4                              |               |
| Accidental                                      | 29                     | –                       | –                                         | 19.8                    | 28    | 1           | N5                              |               |
| Accidental                                      | 29                     | –                       | 6                                         | 19.7                    | 33    | 2           | N6                              |               |
| Accidental                                      | 32                     | –                       | –                                         | 20.8                    | 31    | 13          | N7                              |               |
| Accidental                                      | 28                     | –                       | –                                         | 23.4                    | 27    | 11          | N8                              |               |
| MI                                              | 27                     | –                       | 2                                         | 24.6                    | 32    | 12          | N9                              |               |
| Accidental                                      | 30                     | –                       | –                                         | 21.3                    | 23    | 10          | N10                             |               |
| Accidental                                      | 29                     | –                       | 3                                         | 23.7                    | 34    | 13          | N11                             |               |
| Meth overdose                                    | 29                     | –                       | –                                         | 3                       | 17.9  | 36          | 12                             | M12           |
| Respiratory insufficiency after Meth            | 26                     | 1                       | 3                                         | 10                      | 17.3  | 39          | 11                             | M13           |
| Cardiac arrest after taking Meth                | 13                     | 3                       | 4                                         | 16                      | 17.3  | 39          | 11                             | M13           |
| Cardiac arrest after taking Meth                | 18                     | –                       | 5                                         | 23                      | 18.4  | 45          | 16                             | M14           |
| Cardiac arrest after taking Meth                | 23                     | 1                       | 7                                         | 11                      | 17.6  | 42          | 13                             | M15           |
| Cardiac arrest after taking Meth                | 26                     | –                       | 2                                         | 8                       | 17.2  | 27          | 17                             | M16           |
| Meth overdose                                    | 19                     | 1                       | 3.5                                      | 12                      | 18.7  | 43          | 16                             | M17           |
| Meth overdose                                    | 16                     | 3                       | 4                                         | 12                      | 16.4  | 39          | 16                             | M18           |
| Cardiac arrest after taking Meth                | 24                     | –                       | –                                         | 7                       | 18.3  | 29          | 15                             | M19           |
| Advanced respiratory infection following long-term Meth consumption | 22                     | 1                       | 3                                         | 9                       | 17.7  | 37          | 16                             | M20           |
| Meth overdose                                    | 21                     | –                       | 3                                         | 4                       | 18.9  | 43          | 9                              | M21           |
| Drowning following high Meth intake             | 27                     | –                       | 1.5                                      | 3                       | 19.4  | 22          | 14                             | M22           |
| Brain hemorrhage following excessive Meth consumption | 25                     | –                       | 3.5                                      | 11                      | 17.8  | 40          | 13                             | M23           |
| Falling after taking Meth                        | 14                     | 1                       | 4                                         | 15                      | 17.1  | 46          | 9                              | M24           |
| Meth Overdose                                    | 22                     | –                       | 3                                         | 11                      | 17.8  | 34          | 14                             | M25           |

N: control group, M: Meth group
Nod-like receptor protein 3 and nod-like receptor protein1 inflammasome activation…

cade of danger-associated intracellular signaling pathways subsequently, which activate and promote the NLRP3 inflammasome that induces the noninfectious inflammatory signaling in response to neuronal danger signals (18). Generally, the NLRP3 inflammasome signaling pathway is a specific inflammatory pathway implicated in the initiation and perpetuation of neurotoxicity. Thus, blockade of NLRP3 inflammasome activation might be a promising therapeutic strategy (19). Based on the before mentioned information, the purpose of this study was to explore whether lifetime Meth abuse can induce NLRP1 and NLRP3 upregulation and neuronal apoptosis in the CA1 region of a postmortem hippocampus.

Material and methods

Postmortem human brains were collected from Iranian Legal Medicine Organization. Our ethical consideration in the preservation and sampling of the human brain was based on the Declaration of Helsinki. All procedures were accepted by the Ethics Committee of Shahid Beheshti University of Medical Sciences (IR. SBMU.RETECH.REC.1396.542). The relatives of the deceased persons provided oral consent for the brain donation for purpose of research. The analysis was performed on 14 chronic male Meth users (aged 39 ± 1.9 years) with a drug overdose death. The control group consisted of 11 male adults without any exposure to Meth (aged 38 ± 2 years). In order to prevent post mortem delay, all Control and Meth groups were analyzed within a minimum period of time after death. None of the Meth users had a history of mental illness or neurodegenerative disorders. In addition, none of them was HIV-positive. Methamphetamine drug testing kits were used to detect Meth in the urine samples of both groups.

Sampling and tissue preparation

After obtaining informed consent from the family of the deceased, freshly isolated brain tissues of 14 documented Meth...
Fig. 5. Examination of apoptosis and DNA damage by Tunel assay in Control (upper row) and Meth (lower row) group. Apoptosis increased in the CA1 region of hippocampus of Meth group compared to control. A& D: nuclei stained by DAPI (blue). B&E: apoptotic cells (green). C&F: Merge.

Fig. 4. Immunofluorescence staining in the hippocampal CA1 regions of Control (upper row) and Meth (lower row) group. NLRP3 protein levels increased in the CA1 hippocampus in Meth group compared to control group (p<0.05). A&D: nuclei stained by DAPI (blue). B&E: primary antibody to NLRP3 (green). C&F: merge.

Western blotting
Proteins expressions of NLRP1, NLRP3 were analyzed in the CA1 region of the hippocampus using Western blotting assay. First, tissues were washed by PBS two times and disrupted and homogenized with a sonicator, combined with buffer and transferred to micro-centrifuge tubes and the mixture was centrifuged for 15 minutes. Then it was applied to gel electrophoresis in Sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) to sort the proteins. Afterwards, the separated protein bands were transferred to polyvinylidene difluoride (PVDF) and finally they were examined by primary antibody including rabbit polyclonal anti-NLRP1 (1:200), and human polyclonal anti-NLRP3 (1:200) for detection. The secondary antibodies were conjugated with horseradish peroxidase (HRP) (Cell Signaling Technology, USA). For confirming effective protein transfer during the test, the loading

users and 11 non-addicted from the control group were transported to the lab in lactated Ringer’s solution. After removing blood clots and necrotic tissue, all samples were weighed. For Hematoxylin and Eosin (H&E), Nissl and Golgi staining, immunohistochemistry and tunel assay after dissociation of hippocampus from the brain, it was fixed in 10% formalin for 1 week. Hippocampus was embedded into paraffin blocks and a microtome was used to cut the hippocampus in its longitudinal axis into 5 and 25 μm thick sections (Fig. 1).
control antibody GAPDH generation signal 21 was used.

**Immunohistochemistry**

The brains were Post-fixed (1 week) in 4 % paraformaldehyde and then transferred to 30 % sucrose (Sigma-Aldrich, Germany) solution and were allowed to equilibrate. Afterwards the hippocampuses were sectioned (8 μm in thickness) and stored at −20 °C in a cryoprotectant buffer containing 25 % ethylene, 25 % glycerine and 0.05 M phosphate buffer (all from Sigma-Aldrich, Germany). All slices were incubated with human monoclonal anti-NLRP1 and anti-NLRP3 (Abcam, USA) antibody and diluted to 1:100 overnight in the primary reaction. This process was followed by a similar washing using PBS, and one-hour incubation with goat anti-mouse FITC-conjugated secondary antibody (ab6785, Abcam, USA) at a 1:100 dilution in the second reaction. Finally, the tissue sections were washed with PBS, and the nuclei counterstained using DAPI.

**Stereological study**

**The mean volume of neuron**

The neurons volume was measured by using the nucleator method and calculated with the following equation:

\[ V_n = \frac{4\pi}{3} \times L_n^3 \]

In this formula \( L_n \) is two horizontal directions and was considered from the central point within the nucleolus to the cell or nucleus borders.

**TUNEL assay**

**In situ Cell Death Detection** kit was used to perform Tunel assay (fluorescence, Roche, CH). After fixing the CA1 region of the hippocampus, it was embedded in paraffin, and mounted on glass slides. Then, the paraffin was removed using xylene and it was rehydrated in a piecemeal series of ethanol. After washing with water, Tunel staining was performed and the TUNEL protocols were applied. The results of Meth and control groups were evaluated by Image J software 24.

**Statistical analysis**

Statistical analysis was conducted using IBM SPSS software, version 20.0. The significance level was analyzed using the analysis of variances (ANOVA). Also, for the other statistical comparisons of multiple means in the groups, one-way ANOVA and Tukey’s post hoc test were used. Data in the histograms are presented as mean±SEM, p values <0.05 were considered statistically significant.

**Result**

**Western blot analysis**

NLRP1 and NLRP3 protein expression was determined by Western blot assay. Figure 2 shows the expression of NLRP3 and NLRP1 in the CA1 region of the hippocampus in Control and Meth groups. Western blot analysis showed that NLRP1 and NLRP3 protein expression was significantly increased in the Meth group compared to the control group (p < 0.05). These results confirmed that protein expression level of NLRP3 and NLRP1 increased 0.5-fold in the area CA1 of the hippocampus in the Meth group compared to control group.

**Immunostaining analysis**

The immunohistochemical analyses showed inflammation in the CA1. Level of anti-NLRP1 and anti-NLRP3 antibodies were
analyzed in the CA1 region of hippocampus in Meth and control groups in order to detect the presence of these markers (Figs 3 and 4). As shown in these figures, expression of these protein markers was elevated in the CA1 of the Meth group in comparison with the control group.

**Tunel assay**

After staining the nuclei with DAPI fluorescent dye, the apoptotic cells became Tunel positive and nuclei were merged with positive reaction cells (Fig. 5). Based on the results of Tunel assay (Fig. 5) the average of Tunel positive cells (count/103 mm²) was 50 % in the Meth and 15 % in the control group.

**Hematoxylin and Eosin (H&E), Nissl and Golgi staining analysis**

The result of H&E and Nissl staining showed that the densities of cells are significantly different based on staining results in the Meth and the control groups. The number of cells in control group was significantly higher than in the Meth group. The result of Golgi staining showed that the total length of dendrites was also decreased in Meth groups in comparison with the control groups (Figs 6, 7 and 8).

The volume of neurons

The result of H&E staining showed that the volume of the neuron was significantly reduced in the Meth groups in comparison with the control groups (p < 0.001) (Fig. 9).

**Discussion**

In this study, we have clarified the role of Meth in activating NLRP1, NLRP3 in the hippocampal region. Our results showed that the expression of these markers in Meth group will in long term cause neurodegenerative changes in the hippocampal region. The activation of NLRP3 inflammasome is implicated in microglia-mediated neuroinflammation and dopaminergic neurodegeneration (22). Since in the rodent model exposed to Meth, activated NLRP3 inflammasome was observed, targeting or inhibiting the NLRP3 inflammasome could be a promising strategy for the treatment of drug abuse (23). Abusing Meth which is a strong CNS stimulant may induce neuroinflammation and microglial activation and leads to behavioral and cognitive changes. The precise mechanisms underlying Meth-mediated microglial activation continue to await clarification (24). In this study, after exposing cells to Meth an increase in the level of NLRP1, NLRP3 expression and activation of microglia were reported based on evidence demonstrating morphological changes in cells. Based on our immunostaining analyses, two possible mechanisms for Meth-induced changes to the hippocampus have been proposed. Within the hippocampus, we found increases of NLRP1, NLRP3 expression in Meth group. By interruption of intracellular calcium signaling, Meth could change neural hemostasis leading to tissue damage. Growing evidence has suggested that activating NLRP3 inflammasome may induce neuroinflammation mediated by activated microglia in neurodegenerative disorders such as Parkinson’s disease (25) and Alzheimer’s disease (26). Surprisingly, there is an association between NLRP3 and depression-like behavior according to recent findings (27). After knowing that Meth could activate the NLRP3 inflammasome, the next step was clarifying the upstream mechanisms of regulating NLRP3 activation. Inflammasomes are cytosolic protein complexes that mediate the activation of caspase-1 and IL-1β maturation. The complex regulatory mechanisms remain unclarified. Potassium influx (28),
endoplasmic reticulum stress (29, 30), reactive oxygen species (ROS) and nitric oxide (31, 32) have been considered contributors to activation of the NLRP3 inflammasome. Consistently, Meth increased ROS production in microglia based on our findings (33). Meth abuse can cause cognitive deficits by its neurotoxic effects that are able to induce long-lasting structural and functional changes to the brain (34). Most of the studies of Meth on the human brain come from applying magnetic resonance imaging (MRI) techniques in cross-sectional studies of adult Meth users. In the brain of adult Meth users, several structural abnormalities were evident in the frontal lobe, including decreased gray matter density or volumes (35), increased white matter volumes (36), and increased white matter hyperintensities (37). On the other hand, in the temporal lobe, smaller volumes are evident (38), including the hippocampus (39); but in the parietal cortex and striatal regions, larger volumes have been observed (40). Histologic and stereological results showed that the neurons quantity was decreased in the brain tissue, but glial cells increased. The neurons were shrunk and some of the cells suffered cell death and apoptosis. This study focuses on the effects of Meth in both white and the grey matter of the brain; In fact, Meth may have several effects on the brain using different signaling pathways. Thus, combined immunohistological studies on meth exposed mice are required to elucidate the molecular and cellular mechanisms underlying hippocampus changes. Our results recommend that investigation of histological changes and microglial NLRP3 activation in the hippocamp which that useful in human studies and could be targeted in the treatment of Meth abusers.

Conclusion

Chronic Meth abuse could result in up regulation of NLRP1 and NLRP3 and induction of neuronal apoptosis in the CA1 of the hippocampus in postmortem human brain.

Study limitations

Inadequate access to Meth user’s corpses, lack of information on accurate amount of consumption, and late access to the corpses after death are among the limitation of the study.

References

1. Callaghan RC, Cunningham JK, Sykes J, Kish SJ. Increased risk of Parkinson’s disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. Drug Alcohol Depend 2012; 120: 35–40.
2. Krasnova IN, Cadet JL. Methamphetamine toxicity and messengers of death. Brain Res Rev 2009; 60: 379–407.
3. LaVoie MJ, Card JP, Hastings TG. Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity. Exp Neurol 2004; 187: 47–57.
4. Chang L, Alicata D, Ernst T, Volkow N. Structural and metabolic brain changes in the striatum associated with methamphetamine abuse. Addiction 2007; 102 (Suppl 1): 16–32.
5. Colton CA. Heterogeneity of microglial activation in the innate immune response in the brain. J Neuroimmune Pharmacol 2009; 4: 399–418.
6. Cubells JF, Rayport S, Rajendran G, Sulzer D. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J Neurosci 1994; 14: 2260–2271.
7. Degenhardt L, Mathers B, Guarinieri M, Panda S, Phillips B, Stratdee SA, Tyndall M, Wiessing L, Wodak A, Howard J. Reference Group to the United Nations on HIV, injecting drug use/methamphetamine use and associated HIV: implications for global policy and public health. Int J Drug Policy 2010; 21: 347–358.
8. Dostert C, Petrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008; 320: 674–677.
9. Eskelinen EL. Roles of LAMP-1 and LAMP-2 in lysosome biogenesis and autophagy. Mol Asp Med 2006; 27: 495–502.
10. Flora G, Lee YW, Nath A, Maragos W, Hennig B, Toborek M. Methamphetamine-induced TNF-alpha gene expression and activation of AP-1 in discrete regions of mouse brain potential role of reactive oxygen intermediates and lipid peroxidation. Neuromolecular Med 2002; 2: 71–85.
11. Friend DM, Keefe KA. Glial reactivity in resistance to methamphetamine-induced neurotoxicity. J Neurochem 2013; 125: 566–574.
12. Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson RW. Methamphetamine Treatment Project Corporate Anxiety disorders among methamphetamine dependent adults: association with post-treatment functioning. Am J Addict 2010; 19: 385–390.
13. Gonzalez H, Elgueta D, Montoya A, Pacheco R, Ang A, Rawson R. Methamphetamine-induced neurotoxicity. J Neurochem 2013; 125: 566–574.
14. Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinbeckel T, Fitzgerald KA, Latz E, Moore KJ, Golenbock DT. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 2008; 9: 857–865.
15. Hashimoto K, Tsukada H, Nishiyama S, Fukumoto D, Kakiuchi T, Iyo M. Protective effects of minocycline on the reduction of dopamine transporters in the striatum after administration of methamphetamine: a positron emission tomography study in conscious monkeys. Biol Psychiatry 2007; 61: 577–581.
16. Niknazar S, Nahavandi A, Peyvandi AA, Peyvandi H, Roodzahbany NA, Abbaszadeh HA. Hippocampal NR3C1 DNA methylation can mediate part of preconception paternal stress effects in rat offspring. Behav Brain Res 2017; 324 (1): 71–76.
17. Juliana C, Fernandez-Almenri T, Kang S, Farias A, Qin F, Almenri ES. Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation. J Biol Chem 2012; 287: 36617–36622.
18. Py BF, Kim MS, Vakifahmetoglu-Norberg H, Yuan J. Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity. Mol Cell 2013; 49: 331–338.
19. Ruhl S, Broz P. Caspase-11 activates a canonical NLRP3 inflammasome by promoting K(+) efflux. Eur J Immunol 2015; 45: 2927–2936.
20. Elliott EI, Sutterwala FS. Initiation and perpetuation of NLRP3 inflammasome activation and assembly. Immunol Rev 2015; 265: 35–52.
21. Walsh JG, Mruuve DA, Power C. Inflammasome in the CNS. Nat Rev Neurosci 2014; 15: 84–97.
22. Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saeecker A, Grieb A, Axt D, Remus A, Tzeng TC. NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature 2013; 493: 674–678.

23. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237–241.

24. Di Virgilio F. The therapeutic potential of modifying inflammasomes and NOD-like receptors. Pharmacol Rev 2013; 65: 872–905.

25. Darabi S, Tiraihi T, Noori-Zadeh A, Rajaei F, Darabi L, Abbaszadeh HA. Creatine and retinoic acid effects on the induction of autophagy and differentiation of adipose tissue-derived stem cells into GABAergic-like neurons. J Babol Univ Med Sci 2017; 19: 41–49.

26. Zhu JP, Xu W, Angulo JA. Disparity in the temporal appearance of methamphetamine-induced apoptosis and depletion of dopamine terminal markers in the striatum of mice. Brain Res 2005; 1049: 171–181.

27. Zhang L, Kitaiuchi K, Fujimoto Y, Nakayama H, Shimizu E, Iyo M, Hashimoto K. Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine. Prog. Neuropsychopharmacol. Biol Psychiatry 2006; 30: 1381–1393

28. Yuan J, Hatzidimitriou G, Suthar P, Mueller M, McCann U, Ricarte G. Relationship between temperature, dopaminergic neurotoxicity, and plasma drug concentrations in methamphetamine-treated squirrel monkeys. J Pharmacol Exp Ther 2006; 316: 1210–1218.

29. Ramkissoon A, Wells PG. Methamphetamine oxidative stress, neurotoxicity, and functional deficits are modulated by nuclear factor-E2-related factor 2. Free Radic Biol Med 2015; 89: 358–368.

30. Afanador L, Mexhitaj I, Diaz C, Ordonez D, Baker L, Angulo JA. The role of the neuropeptide somatostatin on methamphetamine and glutamate-induced neurotoxicity in the striatum of mice. Brain Res 2013; 1510: 38–47.

31. Ago M, Ago K, Hara K, Kashimura S, Ogata M. Toxicological and histopathological analysis of a patient who died nine days after a single intravenous dose of methamphetamine: a case report. Leg Med (Tokyo) 2006; 8: 235–239.

32. Brown JM, Riddle EL, Sandoval V, Weston RK, Hanson JE, Crosby MJ, Ugarte YV, Gibb JW, Hanson GR, Fleckenstein AE. A single methamphetamine administration rapidly decreases vesicular dopamine uptake. J Pharmacol Exp Ther 2002; 302: 497–501.

33. Cadet JL, Jayanthi S, Deng X. Methamphetamine-induced neuronal apoptosis involves the activation of multiple death pathways. Review. Neurotoxicity Res 2005; 8: 199–206.

34. Escubedo E, Guittart L, Sureda FX, Jimenez A, Pubill D, Pallas M, Camins A, Camarasa J. Microgliosis and down-regulation of adenosine transporter induced by methamphetamine in rats. Brain Res 1998; 814: 120–126.

35. Noorbakhshnia M, Rashidkaboli A, Pakachtian M, Beheshti S. Agmatine attenuates methamphetamine-induced passive avoidance learning and memory and CaMKII-α gene expression deteriorations in hippocampus of rat. Physiol Behav 2018; 1: 491–496.

36. Bernaskova K, Tomkova S, Slambova R. Are changes in excitability in the hippocampus of adult male rats induced by prenatal methamphetamine exposure or stress? Epilepsy Res 2017; 137: 132–138.

37. McKenna BS, Brown GG, Archibald S, Scadeng M, Bussell R, Keshy JP, Markou A, Soontornniyomkij V, Achim C, Semenova S.Translational Methamphetamine Aids Research Center Tmarc Group. Microstructural changes to the brain of mice after methamphetamine exposure as identified with diffusion tensor imaging. Psychiatry Res Neuroimaging 2016; 30; 249: 27–37.

38. Smith KJ, Butler TR, Prendergast MA. Inhibition of sigma-1 receptor reduces N-methyl-D-aspartate induced neuronal injury in methamphetamine-exposed and -naive hippocampi. Neurosci Lett 2010; 13: 481 (3): 144–148.

39. Simões PF, Silva AP, Pereira FC, Marques E, Grade S, Milhazes N, Borges F, Ribeiro CF, Macedo TR. Methamphetamine induces alterations on hippocampal NMDA and AMPA receptor subunit levels and impairs spatial working memory. Neuroscience 2007; 5; 150 (2): 433–441.

40. Davidson C, Gow AJ, Lee TH, Ellinwood EH. Methamphetamine neurotoxicity: Necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Rev 2001; 36: 1–22.

Received May 11, 2019.
Accepted June 17, 2019.